Iterum launches ORLYNVAH oral UTI treatment in U.S.

Iterum Therapeutics plc has begun the U.S. commercial launch of ORLYNVAH™ (sulopenem etzadroxil and probenecid) oral tablets.

Rhea-AI Filing Summary

Iterum Therapeutics plc has begun the U.S. commercial launch of ORLYNVAH™ (sulopenem etzadroxil and probenecid) oral tablets. The drug is intended to treat adult women with uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae or Proteus mirabilis who have limited or no alternative oral antibacterial options. The launch marks Iterum’s move from development to commercial availability for this product in the United States.

Positive

• U.S. commercial launch of ORLYNVAH™, moving Iterum’s sulopenem etzadroxil and probenecid oral tablets into the market for adult women with limited oral options for uncomplicated urinary tract infections.

Negative

• None.

Insights

Biopharma commercial strategy analyst

Iterum moves sulopenem product into U.S. commercial phase for uUTIs.

Iterum Therapeutics reports the U.S. commercial launch of ORLYNVAH™, an oral combination of sulopenem etzadroxil and probenecid for adult women with uncomplicated urinary tract infections. This represents a transition from purely clinical and regulatory stages into active product commercialization in the U.S. market.

The indication targets infections caused by Escherichia coli, Klebsiella pneumoniae or Proteus mirabilis in patients who have limited or no alternative oral antibacterial options. That focus suggests a niche where resistance or lack of suitable oral therapies is a concern, which can support pricing and positioning, though actual uptake will depend on prescriber adoption, payer coverage, and competition from existing antibiotics.

The filing references a press release dated August 20, 2025 that is furnished as an exhibit, indicating this launch is a current operational milestone. Future disclosures in company filings may provide quantitative data on ORLYNVAH sales, prescribing patterns, and any post-launch safety or market access developments.

8-K Event Classification

2 items: 7.01, 8.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What key event did Iterum Therapeutics plc (ITRM) disclose in this 8-K?

Iterum Therapeutics plc disclosed the U.S. commercial launch of ORLYNVAH™ oral tablets for treating adult women with uncomplicated urinary tract infections.

What is ORLYNVAH and what condition does it treat for Iterum Therapeutics (ITRM)?

ORLYNVAH™ is a combination of sulopenem etzadroxil and probenecid oral tablets, indicated for adult women with uncomplicated urinary tract infections caused by specified bacteria.

Which pathogens are targeted by Iterum Therapeutics’ ORLYNVAH product?

ORLYNVAH™ is indicated for uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae or Proteus mirabilis in adult women.

Why is ORLYNVAH important for patients according to Iterum Therapeutics’ filing?

The filing notes ORLYNVAH™ is for adult women with uncomplicated urinary tract infections who have limited or no alternative oral antibacterial options, addressing a high-need population.

How did Iterum Therapeutics communicate the ORLYNVAH launch to the market?

Iterum issued a press release on August 20, 2025, which is furnished as Exhibit 99.1 and referenced in the 8-K.

Does the Iterum Therapeutics 8-K include financial results related to ORLYNVAH?

The 8-K describes the U.S. commercial launch of ORLYNVAH™ and attaches a press release, but does not provide financial results in the disclosed text.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/20/2025 - 08:15 AM Learn about SEC filing dates

false000165932300-000000000016593232025-08-202025-08-20

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 20, 2025

Iterum Therapeutics plc

(Exact name of Registrant as Specified in Its Charter)

Ireland			001-38503	Not applicable
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
25 North Wall Quay
Dublin 1, , Ireland				Not applicable
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: +353 1 6694820

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary Shares, par value $0.01 per share		ITRM		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On August 20, 2025, Iterum Therapeutics plc (the “Company”) issued a press release announcing the U.S. commercial launch of ORLYNVAH™ (sulopenem etzadroxil and probenecid) oral tablets for the treatment of adult women with uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae or Proteus mirabilis with limited or no alternative oral antibacterial options. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

The information set forth in this Item 7.01 and Exhibit 99.1 attached hereto is “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended.

Item 8.01 Other Events.

On August 20, 2025, the Company announced the U.S. commercial launch of ORLYNVAH™ oral tablets for the treatment of adult women with uncomplicated urinary tract infections (uUTIs) caused by Escherichia coli, Klebsiella pneumoniae or Proteus mirabilis with limited or no alternative oral antibacterial options.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press Release of Iterum Therapeutics plc, dated August 20, 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Iterum Therapeutics plc
Date:	August 20, 2025	By:	/s/ Corey N. Fishman
			Corey N. Fishman Chief Executive Officer